TY - JOUR
T1 - COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models
AU - Maisonnasse, Pauline
AU - Aldon, Yoann
AU - Marc, Aurélien
AU - Marlin, Romain
AU - Dereuddre-Bosquet, Nathalie
AU - Kuzmina, Natalia A.
AU - Freyn, Alec W.
AU - Snitselaar, Jonne L.
AU - Gonçalves, Antonio
AU - Caniels, Tom G.
AU - Burger, Judith A.
AU - Poniman, Meliawati
AU - Bontjer, Ilja
AU - Chesnais, Virginie
AU - Diry, S. golène
AU - Iershov, Anton
AU - Ronk, Adam J.
AU - Jangra, Sonia
AU - Rathnasinghe, Raveen
AU - Brouwer, Philip J. M.
AU - Bijl, Tom P. L.
AU - van Schooten, Jelle
AU - Brinkkemper, Mitch
AU - Liu, Hejun
AU - Yuan, Meng
AU - Mire, Chad E.
AU - van Breemen, Mariëlle J.
AU - Contreras, Vanessa
AU - Naninck, Thibaut
AU - Lemaître, Julien
AU - Kahlaoui, Nidhal
AU - Relouzat, Francis
AU - Chapon, Catherine
AU - Ho Tsong Fang, Raphaël
AU - McDanal, Charlene
AU - Osei-Twum, Mary
AU - St-Amant, Natalie
AU - Gagnon, Luc
AU - Montefiori, David C.
AU - Wilson, Ian A.
AU - Ginoux, Eric
AU - de Bree, Godelieve J.
AU - García-Sastre, Adolfo
AU - Schotsaert, Michael
AU - Coughlan, Lynda
AU - Bukreyev, Alexander
AU - van der Werf, Sylvie
AU - Guedj, J. rémie
AU - Sanders, Rogier W.
AU - van Gils, Marit J.
AU - le Grand, Roger
N1 - Publisher Copyright: © 2021, The Author(s).
PY - 2021/12/1
Y1 - 2021/12/1
N2 - Effective treatments against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) are urgently needed. Monoclonal antibodies have shown promising results in patients. Here, we evaluate the in vivo prophylactic and therapeutic effect of COVA1-18, a neutralizing antibody highly potent against the B.1.1.7 isolate. In both prophylactic and therapeutic settings, SARS-CoV-2 remains undetectable in the lungs of treated hACE2 mice. Therapeutic treatment also causes a reduction in viral loads in the lungs of Syrian hamsters. When administered at 10 mg kg-1 one day prior to a high dose SARS-CoV-2 challenge in cynomolgus macaques, COVA1-18 shows very strong antiviral activity in the upper respiratory compartments. Using a mathematical model, we estimate that COVA1-18 reduces viral infectivity by more than 95% in these compartments, preventing lymphopenia and extensive lung lesions. Our findings demonstrate that COVA1-18 has a strong antiviral activity in three preclinical models and could be a valuable candidate for further clinical evaluation.
AB - Effective treatments against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) are urgently needed. Monoclonal antibodies have shown promising results in patients. Here, we evaluate the in vivo prophylactic and therapeutic effect of COVA1-18, a neutralizing antibody highly potent against the B.1.1.7 isolate. In both prophylactic and therapeutic settings, SARS-CoV-2 remains undetectable in the lungs of treated hACE2 mice. Therapeutic treatment also causes a reduction in viral loads in the lungs of Syrian hamsters. When administered at 10 mg kg-1 one day prior to a high dose SARS-CoV-2 challenge in cynomolgus macaques, COVA1-18 shows very strong antiviral activity in the upper respiratory compartments. Using a mathematical model, we estimate that COVA1-18 reduces viral infectivity by more than 95% in these compartments, preventing lymphopenia and extensive lung lesions. Our findings demonstrate that COVA1-18 has a strong antiviral activity in three preclinical models and could be a valuable candidate for further clinical evaluation.
UR - http://www.scopus.com/inward/record.url?scp=85117693335&partnerID=8YFLogxK
U2 - https://doi.org/10.1038/s41467-021-26354-0
DO - https://doi.org/10.1038/s41467-021-26354-0
M3 - Article
C2 - 34671037
SN - 2041-1723
VL - 12
JO - Nature communications
JF - Nature communications
IS - 1
M1 - 6097
ER -